Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens.

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-3844 Call for proposal: PHRC11

Funded under: PHRC

Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens.

- Summary
- DMPs

Partners

Hôpital Robert Debré , Hôpital Pellegrin , Hôpital Hautepierre (CHRU) , Hôpital Femme-Enfant-Adolescent , Hôpital Jean Minjoz , Hôpital Hôtel-Dieu , Hôpital Jeanne de Flandre , CHU Nantes - Hôtel Dieu , CHU Marseille - Hôpital la Timone , Hôpital Sud Anne de Bretagne , Hôpital Debrousse , Hôpitaux de Brabois Adultes-Enfants , CHU Montpellier - Hôpital Arnaud de Villeneuve , CHUG

Data Management Plans

Start a new DMP in Argos

Found an issue? Give us feedback

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::492ddd7421f5c1a46a76fd7ac6f17d93&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens.

Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens.

Loading